May 07, 2020
Astellas Pharma Inc. has recently reached settlements with a pair of Indian drugmakers that are aiming to make generic versions of its patent-protected overactive bladder treatment Myrbetriq.
October 13, 2016
Astellas Pharma Inc. on Thursday filed three lawsuits in Delaware federal court seeking to block generic versions of its patent-protected overactive bladder treatment Myrbetriq, which were proposed by Aurobindo Pharma, Windlas Healthcare, Prinston Pharmaceutical Inc., Huahai US Inc. and Solco Healthcare US.